companies

Ciliatech

Founded 2017
Employees 2+
Primary contact
178 Route de Cran Gevrier PAE Altaïs
C/o Pepiniere Galileo
74650 Chavanod
France
Links
https://www.cilia.tech/
Diseases & Conditions
Ciliatech is developing a new class of implants to address the increasing need to treat glaucoma durably and with zero adverse effects. The company's groundbreaking concept CID (Cilio-scleral Inter-positioning Device) is the first implant in the industry to reduce intraocular pressure (IOP) without penetrating the anterior chamber or creating subconjunctival filtration - which is a critical criteria that overcome the most serious complications and shortcomings of other glaucoma surgical techniques. As CID is inserted between only two areas of the eye (uniquely between the ciliary body and the sclera), it offers the unparalleled advantage of unlocking the natural uveoscleral pathway without altering the anterior segment of the eye.
Founded 2017
Employees 2+
Primary contact
178 Route de Cran Gevrier PAE Altaïs
C/o Pepiniere Galileo
74650 Chavanod
France
Links
https://www.cilia.tech/
Diseases & Conditions

Funding 💰

Total €6M
Last round 🔗 €3.5M
Series A
April 25, 2023.
Select investors BNP Paribas Développement, Kreaxi, Bpifrance

Key people 🧑‍🤝‍🧑

Highlights ⭐

  • Big addressable market: Glaucoma affects 80 million people per year worldwide. It is also one of the leading causes of blindness for people over the age of 60.
  • It works: The clinical observations of patients using Ciliatech's first-generation CID after 24 months have been very encouraging. Clinical outcomes on the second-generation device are looking even more promising. The company is especially satisfied by the safety profile and the high number of patients still medication-free at 24 months.
  • Transforming surgery: Over the last decade, Ciliatech's founders, Philippe Sourdille, a well-renowned ophthalmic surgeon, and CEO Olivier Benoit, have witnessed great progress in glaucoma surgery. In their view, new developments have enabled the possibility of avoiding the drawbacks of trabeculectomy, the "Gold Standard" surgical technique. Yet, according to Ciliatech, these advances usually require a trade-off, at the expense of obtaining a lower intraocular pressure (IOP) reduction or not sustaining it over time, and/or still show possible significant complications. 🔗

In the news 📰

France's ophthalmology startup Ciliatech raises €3.5M for glaucoma implant device
April 28, 2023

Quotes 💬

“
BNP Paribas Développement is proud to back a visionary team which has developed an innovative implant to treat glaucoma. Thanks to its simple design and smart surgical placement, it will transform patient life by dramatically reducing post-op side effects and medication.
— Sophie Pierrin-Lepinard, investment director at BNP Paribas Développement 🔗
“
Kreaxi is excited by Ciliatech's novel approach to treating glaucoma with long-lasting effect and by the remarkable clinical results we have seen on both first- and second-generations of its implant, CID. Since our initial investment in 2018, the company has demonstrated its ability to fulfil its objectives. This new capital will strengthen Ciliatech's capacity to further its clinical and commercial developments.
— Isabelle Bou Antoun, managing director at Kreaxi 🔗
Last update: May 3, 2023